Another phase 2 clinical trial (NCT01015560) investigating a mAb to human CCL2 (MLN1202, plozalizumab) in bone metastasis of unspecified tumours was conducted in a cohort of 44 subjects.47, 96. This evidence concerns the gene CCL2 and neoplasm.